Baseline demographics
| . | N (%) . |
|---|---|
| Age, median (range), y | 64 (40-80) |
| Sex (male/female) | 35/13 (73%/27%) |
| Race | |
| White | 40 (83%) |
| Asian | 4 (8.3%) |
| Black or African-American | 2 (4.2%) |
| Other | 2 (4.2%) |
| Prior lines of therapy | |
| Median (range) | 3 (1-9) |
| 1 | 19 (40%) |
| 2 | 4 (8.3%) |
| 3 | 8 (16.7%) |
| ≥4 | 17 (35%) |
| ISS | |
| I | 3 (6%) |
| II | 6 (12%) |
| III | 24 (50%) |
| Previous therapy | |
| Auto-SCT | 23 (48%) |
| Immunomodulatory drug | 48 (100%) |
| Lenalidomide | 48 (100%) |
| Pomalidomide | 16 (33%) |
| Proteasome inhibitor | 48 (100%) |
| Bortezomib | 46 (96%) |
| Carfilzomib | 14 (29%) |
| Ixazomib | 3 (6%) |
| CD38 monoclonal antibody∗ | 14 (29%) |
| Daratumumab | 12 (25%) |
| Isatuximab | 2 (4%) |
| Penta-drug exposed† | 6 (13%) |
| FISH | |
| Standard risk | 21 (44%) |
| High risk | 12 (25%) |
| Del17p | 8 (17%) |
| t(4;14) | 3 (6%) |
| t(14;16) | 2 (4%) |
| 1q gain‡ | 14 (29%) |
| Unknown | 15 (31%) |
| . | N (%) . |
|---|---|
| Age, median (range), y | 64 (40-80) |
| Sex (male/female) | 35/13 (73%/27%) |
| Race | |
| White | 40 (83%) |
| Asian | 4 (8.3%) |
| Black or African-American | 2 (4.2%) |
| Other | 2 (4.2%) |
| Prior lines of therapy | |
| Median (range) | 3 (1-9) |
| 1 | 19 (40%) |
| 2 | 4 (8.3%) |
| 3 | 8 (16.7%) |
| ≥4 | 17 (35%) |
| ISS | |
| I | 3 (6%) |
| II | 6 (12%) |
| III | 24 (50%) |
| Previous therapy | |
| Auto-SCT | 23 (48%) |
| Immunomodulatory drug | 48 (100%) |
| Lenalidomide | 48 (100%) |
| Pomalidomide | 16 (33%) |
| Proteasome inhibitor | 48 (100%) |
| Bortezomib | 46 (96%) |
| Carfilzomib | 14 (29%) |
| Ixazomib | 3 (6%) |
| CD38 monoclonal antibody∗ | 14 (29%) |
| Daratumumab | 12 (25%) |
| Isatuximab | 2 (4%) |
| Penta-drug exposed† | 6 (13%) |
| FISH | |
| Standard risk | 21 (44%) |
| High risk | 12 (25%) |
| Del17p | 8 (17%) |
| t(4;14) | 3 (6%) |
| t(14;16) | 2 (4%) |
| 1q gain‡ | 14 (29%) |
| Unknown | 15 (31%) |
Data are presented for 48 patients.
FISH, fluorescence in situ hybridization; ISS, International Staging System; Auto-SCT, autologous stem cell transplantation.
Hundred percent were refractory to anti-CD38 antibody (and also triple-class exposed based on the eligibility criteria for the trial); 7 patients had anti-CD38 antibody as the last line of therapy.
Penta drug included lenalidomide, bortezomib, carfilzomib, pomalidomide, and anti-CD38 antibody.
No patients had 1q amplification (defined as ≥4 copies).